AAM
GNCA

Aberdeen Asset Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Aberdeen Asset Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$86K Buy
2,066
+496
+32% +$23.9K ﹤0.01% 748
2017
Q1 		$76K Buy
+1,570
New +$61.4K ﹤0.01% 738

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Asset Management's GNCA Position: Q2 2017 in Review

Aberdeen Asset Management increased its Genocea Biosciences, Inc. (GNCA) stake by 32% in Q2 2017, buying an estimated $23.9K and bringing the position to 2,066 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #748.

Aberdeen Asset Management first reported a position in GNCA in Q1 2017 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold GNCA as of Q2 2017.

  • Aberdeen Asset Management held 2,066 shares of Genocea Biosciences, Inc. worth $86K as of Q2 2017.
  • Aberdeen Asset Management bought 496 Genocea Biosciences, Inc. shares in Q2 2017, an estimated $23.9K.
  • Genocea Biosciences, Inc. made up ﹤0.01% of Aberdeen Asset Management's portfolio in Q2 2017, its #748 holding.
  • Aberdeen Asset Management first reported a position in Genocea Biosciences, Inc. in Q1 2017 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.